FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1989596707> ?p ?o ?g. }

• W1989596707 endingPage "555" @default.
• W1989596707 startingPage "551" @default.
• W1989596707 abstract "BackgroundAmrubicin, a new anthracycline agent, has shown high activity for small-cell lung cancer (SCLC) with acceptable toxicities in previous studies. However, a combination regimen of platinum and amrubicin for elderly patients has not been reported. In this phase I study, the dose-limiting toxicity (DLT), the maximal tolerable dose (MTD), and the antitumor activity of a combination of amrubicin and carboplatin in elderly patients with SCLC were evaluated.Patients and MethodsPreviously untreated elderly patients (≥70 years old) with SCLC were enrolled in this study. Amrubicin was administered from day 1 to day 3, and carboplatin was administered on day 1 intravenously. The treatment was repeated every 3 weeks. Three escalating dose levels of amrubicin (mg/m2)/carboplatin (area under the curve; AUC) (40/4.0, 40/5.0, and 45/5.0) were initially planned.ResultsTwelve patients were enrolled. At level 1 (amrubicin 40 mg/m2 and carboplatin AUC 4.0), all three patients experienced DLTs (grade 4 neutropenia ≥4 days, thrombocytopenia <20,000/mm3, or grade 3 diarrhea), and this dose level was determined to be the MTD. At the reduced dose of level 0 (amrubicin 35 mg/m2 and carboplatin AUC 4.0), although DLTs were observed in three of the nine patients, they were considered to be clinically not severe and could be managed. Non-hematological toxicities were mild or moderate and reversible. The objective response rate was 83%, and the median survival time was 12.7 months.ConclusionsThe MTD of this combination was amrubicin 40 mg/m2 and carboplatin AUC 4.0, and the recommended dose for a phase II trial is a combination of amrubicin 35 mg/m2 and carboplatin AUC 4.0. We are now conducting a multicenter phase II trial of this regimen to determine the activity of this combination for elderly patients with SCLC. Amrubicin, a new anthracycline agent, has shown high activity for small-cell lung cancer (SCLC) with acceptable toxicities in previous studies. However, a combination regimen of platinum and amrubicin for elderly patients has not been reported. In this phase I study, the dose-limiting toxicity (DLT), the maximal tolerable dose (MTD), and the antitumor activity of a combination of amrubicin and carboplatin in elderly patients with SCLC were evaluated. Previously untreated elderly patients (≥70 years old) with SCLC were enrolled in this study. Amrubicin was administered from day 1 to day 3, and carboplatin was administered on day 1 intravenously. The treatment was repeated every 3 weeks. Three escalating dose levels of amrubicin (mg/m2)/carboplatin (area under the curve; AUC) (40/4.0, 40/5.0, and 45/5.0) were initially planned. Twelve patients were enrolled. At level 1 (amrubicin 40 mg/m2 and carboplatin AUC 4.0), all three patients experienced DLTs (grade 4 neutropenia ≥4 days, thrombocytopenia <20,000/mm3, or grade 3 diarrhea), and this dose level was determined to be the MTD. At the reduced dose of level 0 (amrubicin 35 mg/m2 and carboplatin AUC 4.0), although DLTs were observed in three of the nine patients, they were considered to be clinically not severe and could be managed. Non-hematological toxicities were mild or moderate and reversible. The objective response rate was 83%, and the median survival time was 12.7 months. The MTD of this combination was amrubicin 40 mg/m2 and carboplatin AUC 4.0, and the recommended dose for a phase II trial is a combination of amrubicin 35 mg/m2 and carboplatin AUC 4.0. We are now conducting a multicenter phase II trial of this regimen to determine the activity of this combination for elderly patients with SCLC." @default.
• W1989596707 created "2016-06-24" @default.
• W1989596707 creator A5007143858 @default.
• W1989596707 creator A5010341904 @default.
• W1989596707 creator A5013199621 @default.
• W1989596707 creator A5017693924 @default.
• W1989596707 creator A5037746646 @default.
• W1989596707 creator A5047333567 @default.
• W1989596707 creator A5076854153 @default.
• W1989596707 creator A5077670186 @default.
• W1989596707 creator A5081243390 @default.
• W1989596707 creator A5084226714 @default.
• W1989596707 date "2006-07-01" @default.
• W1989596707 modified "2023-10-03" @default.
• W1989596707 title "A Phase I Study of Amrubicin Combined with Carboplatin for Elderly Patients with Small-Cell Lung Cancer" @default.
• W1989596707 cites W1995022001 @default.
• W1989596707 cites W2056631765 @default.
• W1989596707 cites W2082851735 @default.
• W1989596707 cites W2083461199 @default.
• W1989596707 cites W2100255788 @default.
• W1989596707 cites W2108882850 @default.
• W1989596707 cites W2110182487 @default.
• W1989596707 cites W2121717811 @default.
• W1989596707 cites W2123927174 @default.
• W1989596707 cites W2138011982 @default.
• W1989596707 cites W2165870910 @default.
• W1989596707 doi "https://doi.org/10.1016/s1556-0864(15)30358-0" @default.
• W1989596707 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17409916" @default.
• W1989596707 hasPublicationYear "2006" @default.
• W1989596707 type Work @default.
• W1989596707 sameAs 1989596707 @default.
• W1989596707 citedByCount "9" @default.
• W1989596707 countsByYear W19895967072014 @default.
• W1989596707 countsByYear W19895967072017 @default.
• W1989596707 countsByYear W19895967072019 @default.
• W1989596707 crossrefType "journal-article" @default.
• W1989596707 hasAuthorship W1989596707A5007143858 @default.
• W1989596707 hasAuthorship W1989596707A5010341904 @default.
• W1989596707 hasAuthorship W1989596707A5013199621 @default.
• W1989596707 hasAuthorship W1989596707A5017693924 @default.
• W1989596707 hasAuthorship W1989596707A5037746646 @default.
• W1989596707 hasAuthorship W1989596707A5047333567 @default.
• W1989596707 hasAuthorship W1989596707A5076854153 @default.
• W1989596707 hasAuthorship W1989596707A5077670186 @default.
• W1989596707 hasAuthorship W1989596707A5081243390 @default.
• W1989596707 hasAuthorship W1989596707A5084226714 @default.
• W1989596707 hasBestOaLocation W19895967071 @default.
• W1989596707 hasConcept C121608353 @default.
• W1989596707 hasConcept C126322002 @default.
• W1989596707 hasConcept C143998085 @default.
• W1989596707 hasConcept C2776256026 @default.
• W1989596707 hasConcept C2776694085 @default.
• W1989596707 hasConcept C2776802502 @default.
• W1989596707 hasConcept C2777063308 @default.
• W1989596707 hasConcept C2778239845 @default.
• W1989596707 hasConcept C2778850193 @default.
• W1989596707 hasConcept C2781413609 @default.
• W1989596707 hasConcept C2781451048 @default.
• W1989596707 hasConcept C530470458 @default.
• W1989596707 hasConcept C71924100 @default.
• W1989596707 hasConcept C90924648 @default.
• W1989596707 hasConceptScore W1989596707C121608353 @default.
• W1989596707 hasConceptScore W1989596707C126322002 @default.
• W1989596707 hasConceptScore W1989596707C143998085 @default.
• W1989596707 hasConceptScore W1989596707C2776256026 @default.
• W1989596707 hasConceptScore W1989596707C2776694085 @default.
• W1989596707 hasConceptScore W1989596707C2776802502 @default.
• W1989596707 hasConceptScore W1989596707C2777063308 @default.
• W1989596707 hasConceptScore W1989596707C2778239845 @default.
• W1989596707 hasConceptScore W1989596707C2778850193 @default.
• W1989596707 hasConceptScore W1989596707C2781413609 @default.
• W1989596707 hasConceptScore W1989596707C2781451048 @default.
• W1989596707 hasConceptScore W1989596707C530470458 @default.
• W1989596707 hasConceptScore W1989596707C71924100 @default.
• W1989596707 hasConceptScore W1989596707C90924648 @default.
• W1989596707 hasIssue "6" @default.
• W1989596707 hasLocation W19895967071 @default.
• W1989596707 hasLocation W19895967072 @default.
• W1989596707 hasOpenAccess W1989596707 @default.
• W1989596707 hasPrimaryLocation W19895967071 @default.
• W1989596707 hasRelatedWork W1975832547 @default.
• W1989596707 hasRelatedWork W1983784941 @default.
• W1989596707 hasRelatedWork W1989596707 @default.
• W1989596707 hasRelatedWork W1991613108 @default.
• W1989596707 hasRelatedWork W2022084568 @default.
• W1989596707 hasRelatedWork W2050471259 @default.
• W1989596707 hasRelatedWork W2107842653 @default.
• W1989596707 hasRelatedWork W2162555812 @default.
• W1989596707 hasRelatedWork W2383272827 @default.
• W1989596707 hasRelatedWork W4297377461 @default.
• W1989596707 hasVolume "1" @default.
• W1989596707 isParatext "false" @default.
• W1989596707 isRetracted "false" @default.
• W1989596707 magId "1989596707" @default.
• W1989596707 workType "article" @default.